
Revolution Medicines (RVMD) shares soared on April 13 after the biotech firm said its pancreatic cancer drug, daraxonrasib, demonstrated an “unprecedented survival rate” in a Phase 3 clinical trial.
The upward momentum helped RVMD break above its key moving averages (20-day and 50-day), indicating that near-term momentum is shifting in favor of the bulls.